Xuefei Wang,
Hongyong He,
Heng Zhang,
Weidong Chen,
Yuan Ji,
Zhaoqing Tang,
Yong Fang,
Cong Wang,
Fenglin Liu,
Zhenbin Shen,
Jing Qin,
Yu Zhu,
Haiou Liu,
Jiejie Xu, Jianxin Gu,
Xinyu Qin,
Yihong Sun
[show abstract]
[hide abstract]
ABSTRACT: Aberrant β1, 6-N-acetylglucosaminyltransferase V (MGAT5) expressions in malignant tissues have been reported to involve in various cancer development and progression via altering N-glycan branching. We aim to investigate the clinical and prognostic values of MGAT5 and improve the risk stratification in patients with gastric cancer. MGAT5 expression was retrospectively analyzed by immunohistochemistry in three independent sets comprising 313 patients with gastric adenocarcinoma from China. Results were assessed for association with clinical features and overall survival by using Kaplan-Meier analysis. Prognostic values of MGAT5 expression and clinical outcomes were evaluated by Cox regression analysis. A molecular prognostic stratification scheme incorporating MGAT5 expression was determined in patients with late-stage gastric cancer by using receiver operating characteristic (ROC) analysis. The results show that low intratumoral MGAT5 density, which was associated with poor differentiation, N classification, TNM stage, and Kiel stage, was an independent prognosticator for poor overall survival. Combination of intratumoral MGAT5 expression and TNM or Kiel staging systems had a better predictive power for overall survival. Applying the prognostic value of intratumoral MGAT5 density to TNM stage III+IV and Kiel stage IIIB+IV groups showed a better risk stratification for overall survival in patients with late-stage gastric cancer. In conclusion, integrating intratumoral MGAT5 density that was recognized as an independent prognostic marker into current clinical staging systems significantly improved prognostic stratification of patients with late-stage gastric cancer. This refined risk stratification scheme might aid in appropriate therapeutic options and ultimately improve the outcomes of patients with advanced-stage disease.
Cancer Science 10/2012; · 3.33 Impact Factor
